Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Staphylococcal Infections Clinical Trial

Official title:

A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01364571
• Other study ID #: B3451001
• Secondary ID: 6123K1-1005
• Status: Completed
• Phase: Phase 1
• Start date: August 2011
• Est. completion date: January 2013

Study information

• Verified date: February 2019
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 18 to <65 years. In addition, the study aims to assess the effect of the SA4Ag vaccine on the presence of the Staphylococcus aureus on the skin and within the nose, throat and perineum of healthy adults aged 18 to <65 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 456
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Healthy adults aged 18 to <65 years at enrollment, as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included.

• Availability for the entire duration of the study, and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including completion of the electronic diary (e-diary) from Day 1 to Day 14 following vaccination(s).

• Ability to be contacted by telephone during study participation.

• All male and female subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study.

Exclusion Criteria:

• Unstable chronic medical condition or disease requiring significant change in therapy or hospitalization within 3 months before receipt of study vaccine.

• Serious chronic medical disorders and any other disorder that in the investigator's opinion precludes the subject from participating in the study

• Donation of blood volume of 250 mL or greater (excluding protocol-required blood collection), or donation of plasma within 3 months prior to enrollment.

• Bleeding condition associated with prolonged bleeding time that may contraindicate intramuscular injection or blood draw including subjects taking anticoagulant, antiplatelet and/or antithrombotic agents except for low-dose daily aspirin within 30 days before enrollment through 1 month post-vaccination.

• Any contraindication to vaccination or vaccine components.

• Immunocompromised persons and subjects currently on immunosuppressive therapy or with a history of immunosuppressive therapy, including chemotherapy agents or long term systemic corticosteroids.

• Previous administration of S. aureus vaccination.

• Any infection proven or suspected to be caused by S. aureus within 6 months preceding study vaccination.

• Receipt of blood products or immunoglobulins (including monoclonal antibodies) within 12 months before enrollment through conclusion of the study.

• Participation in other investigational or interventional studies within 30 days before the current study begins and/or during study participation.

• Subjects who are investigational site staff members or subjects who are immediate family members (1st degree relatives) of investigational site staff members or Pfizer employees directly involved in the conduct of the trial.

• Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.

• For Phase 1 subjects only, any abnormality in screening hematology, coagulation and/or blood chemistry laboratory values.

• Women who are pregnant (as determined by urine pregnancy test) or breastfeeding.

• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Related Conditions & MeSH terms

• Staphylococcal Infections

Intervention

Biological:
• SA4Ag vaccine low dose
Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.

Procedure:
• Blood draw
Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
• Colonization swab sample
Colonization swabs will be collected from all subjects at various time points throughout the study.

Biological:
• SA4Ag vaccine mid dose
Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.

Procedure:
• Blood sample
Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
• Colonization swab sample
Colonization swabs will be collected from all subjects at various time points throughout the study.

Biological:
• SA4Ag vaccine high dose
Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.

Procedure:
• Blood draw
Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
• Colonization swab sample
Colonization swabs will be collected from all subjects at various time points throughout the study.

Biological:
• Placebo
Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.

Procedure:
• Blood draw
Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
• Colonization swab sample
Colonization swabs will be collected from all subjects at various time points throughout the study.

Locations

Country	Name	City	State
United States	Benchmark Research	Austin	Texas
United States	Roberta Braun, M.D.	Austin	Texas
United States	SNBL Clinical Pharmacology Center, Inc.	Baltimore	Maryland
United States	Kentucky Pediatric/Adult Research	Bardstown	Kentucky
United States	Buffalo Clinical Research Center, LLC	Buffalo	New York
United States	PMG Research of Raleigh, LLC d/b/a PMG Research of Cary	Cary	North Carolina
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Broward Research Group	Hollywood	Florida
United States	Texas Center for Drug Development, Inc.	Houston	Texas
United States	New Orleans Center for Clinical Research	Knoxville	Tennessee
United States	Volunteer Research Group	Knoxville	Tennessee
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Vince and Associates Clinical Research	Overland Park	Kansas
United States	Prism Research	Saint Paul	Minnesota
United States	Miami Research Associates	South Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and proportion of subjects reporting local reactions (size of redness and/or swelling and severity of pain at the injection site) and severity of the local reactions as self-reported on electronic diaries (e-diaries)		14 days
Primary	Number and proportion of subjects reporting solicited systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain) and severity of solicited systemic events self-reported on electronic diaries		14 days
Primary	Number and proportion of subjects reporting unsolicited AEs and serious adverse events (SAEs) categorized according to the Medical Dictionary for Regulatory Activities (MedDRA)		1 month (AEs), 6 months (SAEs)
Primary	Number and proportion of Phase 1 subjects with abnormal hematology, coagulation and blood chemistry lab assessments; number and proportion of Phase 1 subjects with grading shifts in hematology, coagulation and blood chemistry laboratory assessments.		14 days
Primary	Proportion of subjects achieving antibody responses to specific antigens with results greater than or equal to thresholds specific to each of the 4 antigens in the vaccine based on immunoglobulin-binding and/or opsonophagocytic activity assays.		1 month
Secondary	Immunoglobulin concentrations for each antigen at each applicable blood sampling time point,		various, up to 12 months
Secondary	Opsonophagocytic activity (OPA) titers at each applicable blood sampling time point,		1 month
Secondary	Immunoglobulin geometric mean fold rise (GMFR) for each antigen		1 month
Secondary	Geometric mean fold rise on opsonophagocytic activity assay titers		1 month
Secondary	Proportion of subjects achieving antibody responses to specific antigens with results greater than or equal to thresholds specific to each of the 4 antigens in the vaccine at at each applicable visit		various, up to 12 months